Publication | Closed Access

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

Isolated SyndromeRheumatologyRelapsing-remitting Multiple SclerosisClinical TherapeuticNeurological ProgressClinical TrialsPharmacotherapyNeurologyMultiple SclerosisMedicinePhase 3